Pricing Log in Create free account

Lakefront Biotherapeutics - Sponsored ADR (LKFT) vs NewAmsterdam Pharma Company N.V. (NAMS)

Lakefront Biotherapeutics - Sponsored ADR and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. Lakefront Biotherapeutics - Sponsored ADR and NewAmsterdam Pharma Company N.V. are of similar size ($2.3B and $2.2B). NewAmsterdam Pharma Company N.V. grew revenue faster over the last twelve months: −26.4% against −52.2%. Lakefront Biotherapeutics - Sponsored ADR has the higher net margin (−6.81% vs −789.9%) and the higher return on invested capital (0.00% vs −13,975.8%). Across the 17 metrics below, Lakefront Biotherapeutics - Sponsored ADR leads on 13 and NewAmsterdam Pharma Company N.V. on 4.

Valuation

Metric LKFT NAMS Biotechnology median
P/E n/m n/m 10.60
P/S 7.79 91.03 9.40
P/B 0.58 3.74 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.96 n/m 0.66
EV/Sales (1.42) 66.75 9.02
Earnings yield (0.85%) (8.89%) (32.88%)
Free cash flow yield (27.14%) (6.39%) (23.13%)

Profitability

Metric LKFT NAMS Biotechnology median
Gross margin 89.75% 100.00% 68.51%
Operating margin (90.11%) (900.07%) 0.00%
Net margin (6.81%) (789.94%) 0.00%
Free cash flow margin 0.00% (581.64%) 0.00%
Return on equity 0.00% (30.16%) (51.96%)
Return on assets 0.00% (27.79%) (46.06%)
Return on invested capital 0.00% (13,975.75%) 0.00%

Growth

Metric LKFT NAMS Biotechnology median
Revenue growth (TTM) (52.22%) (26.41%) 6.76%
EPS growth (last fiscal year) 355.37% 32.81% 29.88%
Revenue growth, 5-year CAGR 15.75% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LKFT NAMS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 32.84 11.76 4.97
Net debt to EBITDA (8.53) 2.83 1.01

Dividend

Metric LKFT NAMS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LKFT NAMS Biotechnology median
Market cap 2.20b 2.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack